Virax Biolabs Group Ltd (VRAX) Corporate Subsidiaries
Virax Biolabs Group Ltd (VRAX) is a publicly traded company on the Nasdaq, categorized under SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: VRAX
CIK: 1885827
Exchange: Nasdaq
SIC 2835: In Vitro & In Vivo Diagnostic Substances
Fiscal Year End: 03/31
State: E9
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Reliant CPA PC
Auditor SinceSince 3/31/2023 12:00:00 AM
Lead Engagement PartnerBrian Rusywick
Audit LocationNewport Beach, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 6-K | 2026-10-09 | 2026-10-09 | 6-K | 0001193125-26-419117 | View SEC Doc Filr Page |
| 424B3 | 2026-09-10 | — | 424B3 | 0001193125-26-386697 | View SEC Doc Filr Page |
| 6-K | 2026-09-04 | 2026-09-04 | 6-K | 0001193125-26-383683 | View SEC Doc Filr Page |
| 424B5 | 2026-09-04 | — | 424B5 | 0001193125-26-383658 | View SEC Doc Filr Page |
| EFFECT | 2026-09-03 | — | EFFECT Filing | 9999999995-26-002878 | View SEC Doc Filr Page |
| F-3/A | 2026-09-02 | — | F-3/A | 0001193125-26-380474 | View SEC Doc Filr Page |
| 6-K | 2026-08-26 | 2026-08-21 | 6-K | 0001193125-26-368710 | View SEC Doc Filr Page |
| 6-K | 2026-08-18 | 2026-08-18 | 6-K | 0001193125-26-354722 | View SEC Doc Filr Page |
| 6-K | 2026-07-31 | 2026-07-31 | 6-K | 0001193125-26-326851 | View SEC Doc Filr Page |
| F-3 | 2026-07-24 | — | F-3 | 0001193125-26-316130 | View SEC Doc Filr Page |
| 6-K | 2026-07-16 | 2026-07-16 | 6-K | 0001193125-26-305400 | View SEC Doc Filr Page |
| 6-K | 2026-07-10 | 2026-07-10 | 6-K | 0001193125-26-300880 | View SEC Doc Filr Page |
| 6-K | 2026-07-09 | 2026-07-09 | 6-K | 0001193125-26-299132 | View SEC Doc Filr Page |
| 20-F | 2026-07-06 | 2026-03-31 | 20-F | 0001193125-26-295158 | View SEC Doc Filr Page |
| 6-K | 2026-06-24 | 2026-06-24 | 6-K | 0001193125-26-281196 | View SEC Doc Filr Page |
| 6-K | 2026-06-12 | 2026-06-12 | 6-K | 0001193125-26-268604 | View SEC Doc Filr Page |
| 6-K | 2026-05-26 | 2026-05-26 | 6-K | 0001193125-26-237882 | View SEC Doc Filr Page |
| 6-K | 2026-05-22 | 2026-05-22 | 6-K | 0001193125-26-236980 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001172661-26-002143 | View SEC Doc Filr Page |
| 6-K | 2026-04-14 | 2026-04-14 | 6-K | 0001193125-26-153963 | View SEC Doc Filr Page |
| 6-K | 2026-04-10 | 2026-04-10 | 6-K | 0001193125-26-151292 | View SEC Doc Filr Page |
| 3 | 2026-03-31 | 2026-03-18 | 3 | 0001193125-26-134281 | View SEC Doc Filr Page |
| 3 | 2026-03-20 | 2026-03-18 | 3 | 0000950130-26-000117 | View SEC Doc Filr Page |
| 6-K | 2026-03-18 | 2026-03-18 | 6-K | 0001193125-26-114283 | View SEC Doc Filr Page |
| 3 | 2026-03-18 | 2026-03-18 | 3 | 0001193125-26-113908 | View SEC Doc Filr Page |